<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Anaesthesiol Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">J Anaesthesiol Clin Pharmacol</journal-id><journal-id journal-id-type="publisher-id">JOACP</journal-id><journal-id journal-id-type="publisher-id">J Anaesthesiol Clin Pharmacol</journal-id><journal-title-group><journal-title>Journal of Anaesthesiology, Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0970-9185</issn><issn pub-type="epub">2231-2730</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9438807</article-id><article-id pub-id-type="publisher-id">JOACP-38-136</article-id><article-id pub-id-type="doi">10.4103/joacp.JOACP_674_20</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to Editor</subject></subj-group></article-categories><title-group><article-title>Prolonged SARS-CoV-2 RT-PCR positivity in a patient with aneurysmal subarachnoid hemorrhage</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Krishnaswamy</surname><given-names>Sharath</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Surve</surname><given-names>Rohini M.</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Kamath</surname><given-names>Sriganesh</given-names></name><xref rid="aff1" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Department of Neuroanaesthesia and Neurocritical Care, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India</aff><author-notes><corresp id="cor1">
<bold>Address for correspondence:</bold> Dr. Rohini M. Surve, Department of Neuroanaesthesia and Neurocritical Care, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru - 560 029, Karnataka, India. E-mail: <email xlink:href="rohinigondhule@gmail.com">rohinigondhule@gmail.com</email>
</corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>01</day><month>4</month><year>2022</year></pub-date><volume>38</volume><issue>Suppl 1</issue><fpage>S136</fpage><lpage>S137</lpage><history><date date-type="received"><day>24</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2022 Journal of Anaesthesiology Clinical Pharmacology</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions></article-meta></front><body><p>Dear Editor,</p><p>The median duration of SARS-CoV-2 infection is about 20&#x02013;28 days and longer in elderly, those with comorbidities, severe infection and immunosuppression. Few reports have documented positive RT-PCR up to 60&#x02013;63 days.[<xref rid="R1" ref-type="bibr">1</xref><xref rid="R2" ref-type="bibr">2</xref>]</p><p>We report prolonged SARS-CoV-2 RT-PCR positivity in a patient with aneurysmal subarachnoid hemorrhage (aSAH) and discuss the dilemma and implications of managing such a patient.</p><p>A 55-year-old woman presented with a 1-day history of headache, dizziness, and vomiting. At presentation, her Glasgow Coma Scale score was E4V1M5 with equal and responsive pupils. She was receiving telmisartan for hypertension management. Following imaging, she was diagnosed with aSAH, secondary to rupture of anterior communicating artery aneurysm.</p><p>As per our hospital policy in June 2020, COVID-19 score &#x02265;5, based on the exposure risks and clinical manifestations, was an indication for SARS-CoV-2 RT-PCR testing. This patient with a score of 6 tested positive for COVID-19 on day 5 of presentation. She was intubated and managed in a COVID-19-dedicated ICU. Surgical intervention was not considered in view poor neurological status. Chest imaging on day 3 revealed fibrotic changes in the left lung with tractional bronchiectasis [<xref rid="JOACP_674_20-f001" ref-type="fig">Figure 1</xref>]. Later, she developed pneumonia requiring strategies to improve oxygenation and ventilation. Her medical management included paracetamol, mannitol, morphine, nimodipine, dexamethasone, azithromycin, zinc, multivitamins, and antibiotics based on culture sensitivity. Despite elevated D-dimer (2945 ng/dL) on day 8, heparin was delayed till 14<sup>th</sup> day due to concerns of aneurysmal rebleeding. Inflammatory markers such as C-reactive protein (CRP) and lactate dehydrogenase remained elevated till day 58. Alkaline phosphatase (ALP) was also high throughout the hospital stay (481&#x02013;1766 U/L). She underwent surgical tracheostomy as her neurological status remained poor and weaning was unsuccessful. RT-PCR test repeated on days 15, 23, 31, 38, 44, and 56, persistently remained positive. The patient became weakly positive for COVID-19 IgG antibodies on day 61 with titers of 5.87 and turned RT-PCR negative on day 66. She was discharged from the hospital on day 86 in same neurological status.</p><fig position="float" id="JOACP_674_20-f001"><label>Figure 1</label><caption><p>(a) Frontal chest radiograph reveals left lung fibrosis. Non-contrast CT thorax (b and c) shows left lung fibrotic changes along with tractional bronchiectasis</p></caption><graphic xlink:href="JOACP-38-136-g001" position="float"/></fig><p>Mortality is high in neurological patients with concomitant COVID-19 infection.[<xref rid="R3" ref-type="bibr">3</xref>] Prolonged SARS-CoV-2 RT-PCR positivity in neurosurgical patients results in dilemma regarding certain management aspects (anticoagulation, surgery, imaging, COVID-19 ICU care) and can adversely impact outcomes. SARS-CoV-2 viral replication is prolonged in elderly patients with comorbidities. Relapse or rebound infection is a concern in patients with persistently positive on RT-PCR[<xref rid="R4" ref-type="bibr">4</xref>] and possibility of infection transmission cannot be completely negated. In the absence of viral culture, it is unclear if occurrence of prolonged nucleic acid conversion contributes to prolonged infectivity. Virus infectivity decreases when RT-PCR cycle threshold (Ct) values are &#x0003e;24 and Ct values of are inversely related to viral load.[<xref rid="R5" ref-type="bibr">5</xref>] However, viral culture are not routinely done, and Ct values of RT-PCR are not generally reported. Their utility should be explored in prolonged RT-PCR positive situations to decide discontinuation of infection transmission precautions. To conclude, prolonged SARS-CoV-2 RT-PCR positivity not only has financial and clinical implications, but also precludes an opportunity for other potentially salvageable patients requiring COVID-ICU care.</p><sec disp-level="2"><title>Declaration of patient consent</title><p>The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.</p></sec><sec disp-level="2"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec sec-type="COI-statement" disp-level="2"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Baihui</surname><given-names>L</given-names></name>
<name><surname>Song</surname><given-names>D</given-names></name>
</person-group><article-title>Case report: Viral shedding for 60 days in woman with Novel coronavirus disease</article-title><source>Am J Trop Med Hyg</source><year>2020</year><volume>102</volume><fpage>1210</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">32342849</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>WD</given-names></name>
<name><surname>Chang</surname><given-names>SY</given-names></name>
<name><surname>Wang</surname><given-names>JT</given-names></name>
<name><surname>Tsai</surname><given-names>MJ</given-names></name>
<name><surname>Hung</surname><given-names>CC</given-names></name>
<name><surname>Hsu</surname><given-names>CL</given-names></name>
<etal/>
</person-group><article-title>Prolonged virus shedding after seroconversion in patient with COVID-19</article-title><source>J Infect</source><year>2020</year><volume>81</volume><fpage>318</fpage><lpage>56</lpage></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Surve</surname><given-names>RM</given-names></name>
<name><surname>Mishra</surname><given-names>RK</given-names></name>
<name><surname>Malla</surname><given-names>SR</given-names></name>
<name><surname>Kamath</surname><given-names>S</given-names></name>
<name><surname>Chakrabarti</surname><given-names>DR</given-names></name>
<name><surname>Kulanthaivelu</surname><given-names>K</given-names></name>
<etal/>
</person-group><article-title>Clinical Characteristics and Outcomes of Critically Ill Neurological Patients with COVID-19 Infection in Neuro-intensive Care Unit: A Retrospective Study</article-title><source>Indian J Crit Care Med.</source><year>2021</year><volume>25</volume><fpage>1126</fpage><lpage>1132</lpage><comment>doi: 10.5005/jp-journals-10071-23989</comment><pub-id pub-id-type="pmid">34916744</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Gousseff</surname><given-names>M</given-names></name>
<name><surname>Penot</surname><given-names>P</given-names></name>
<name><surname>Gallay</surname><given-names>L</given-names></name>
<name><surname>Batisse</surname><given-names>D</given-names></name>
<name><surname>Benech</surname><given-names>N</given-names></name>
<name><surname>Bouiller</surname><given-names>K</given-names></name>
<etal/>
</person-group><article-title>Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?</article-title><source>J Infect</source><year>2020</year><volume>81</volume><fpage>816</fpage><lpage>46</lpage></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author">
<name><surname>Bullard</surname><given-names>J</given-names></name>
<name><surname>Dust</surname><given-names>K</given-names></name>
<name><surname>Funk</surname><given-names>D</given-names></name>
<name><surname>Strong</surname><given-names>JE</given-names></name>
<name><surname>Alexander</surname><given-names>D</given-names></name>
<name><surname>Garnett</surname><given-names>L</given-names></name>
<etal/>
</person-group><article-title>Predicting infectious SARS-CoV-2 from diagnostic samples</article-title><source>Clin Infect Dis</source><year>2020</year><comment>ciaa638. doi: 10.1093/cid/ciaa638. Online ahead of print</comment></element-citation></ref></ref-list></back></article>
